Comprehensive Quality Care in Kidney Diseases and Hypertension in Western Australia

Resume- Dynamic

CURRENT POSITIONS:

  • Clinical Associate Professor- University of Western Australia (Dept of Medicine) – February 2025 till date
  • Senior Lecturer, Curtin Medical School Western Australia – 2008 till date
  • Head of Department – Armadale Renal Services – Armadale Health Services WA June 2004 – till date
  • Renal Physician – Royal Perth Hospital and Health Services (Post reconfiguration of Health Services): Feb 2015 – till date
  • Renal Physician – St John of God Health Care (Murdoch): Jun 2004 till date
  • Renal Physician: Mount Hospital – June 2004 – till date.
  • Dobney Hypertension Centre, Medical Research Foundation, Royal Perth Hospital, Perth.
  • Linear Research Institute, Nedlands.

PAST POSITIONS:

  • Renal Physician – Peel Health Campus (Mandurah)- June 2004 till Dec 2023
  • Co –Clinical Lead, Renal Health Network, Health Networks Branch, Dept of Health, WA 2012 – till Jun 2020
  • Renal Physician – Fremantle Hospital and Health Services June 2004 – Jan 2015

GRANTS & AWARDS:

  • Feb 2014: Assoc Investigator for NHMRC Grant  for Feb 2014: APP1079502 Chronic Kidney Disease Centre of Research Excellence https://cre-ckd.centre.uq.edu.au/profile/95/hemant-kulkarni
  • June 2013: Kidney Health Australia: OPERATION ANGEL Award: For Inspirational Contribution to the patients with Kidney Care in Western Australia
  • 2012- 2013: ANZSN-Amgen Quality Assurance Grant ($ 10,000) for assessment of the development of Vascular access centre in Outer Metropolitan Hospital
  • 2007: ANZSN- NEPHROLOGY RESEARCH GRANT ($ 35,000) for clinical research in Iron Overload in Haemodialysis population
  • 1997: First Rank in University of Mumbai for DM (Nephrology) examination
  • Dec 1994: Pfizer Postgraduate Medical Award & Medallion & Scroll of honour for securing highest marks in Medicine in MBBS
  • 1990-1991: N F Surveyor Gold Medal for 1ts Rank in MBBS at Grant Medical College, University of Mumbai
  • March 1991: Prof M B Gharpure Memorial Prize (1st in Pharmacology) at Grant Medical College, University of Mumbai
  • Merit awards and Scholarships by Govt of India and Maharashtra: HSC certification

QUALIFICATIONS:

  • 2003: FRACP: Royal Australasian College of Physicians
  • 2002: AMC: Australasian Medical Council Examinations
  • 1999: MRCPCH (UK): Royal College of Physicians, United Kingdom
  • 1997: DM (NEPHROLOGY): Doctor of Medicine, University of Mumbai, India (!st rank in Univ of Mumbai)
  • 1995: MD (PEDIATRICS): Doctor of Medicine, University of Mumbai, India
  • 1994: DCH: College of Physicians and Surgeons, Mumbai, India
  • 1992: MBBS : Grant Medical College, University of Mumbai, India (1st rank in Grant Medical College)

PUBLICATIONS:

RESEARCH GATE: https://www.researchgate.net/profile/Hemant_Kulkarni2/publications

Public URL for Google Scholar http://scholar.google.com.au/citations?user=gRzjH2wAAAAJ

  • Lijun Zhong, D Chan, Hemant Kulkarni, J Jamboti: Preserving Residual Kidney Function in Haemodialysis: Current Practices in Western Australia. Minioral Presentation, Renal Society of Australasia, 2025.
  • Potter, Daniela; Conway, Annie: Davies, Christopher; Kotwal, Sradha: Pilmore, Andrew; Menahem, Solomon; Kulkarni, Hemant; Roberts, Mathew Blake; Kolovos, Peter; Thomas, Subi; Dendle, Claire; Irish, Georgina; Polkinghorne, Kevan. Changes in dialysis practice patterns in Australia and New Zealand during the COVID-19 pandemic period: An ANZDATA observational cohort study. In process of submission (March 2025)
  • Peter Kolovos, Christopher E Davies, Feruza Kholmurodova, Georgina Irish, Hemant Kulkarni, …., Solomon Menahem. Risk factors associated with 30-day mortality following COVID-19 infection in patients receiving kidney replacement therapy in Australian and New Zealand.: to CKJ June 2024
  • Light C, Heslop K, Kulkarni H. Comparison of Factors Affecting the Immune Response to Hepatitis B Vaccination in Patients with Stage 5 Chronic Kidney Disease-haemodialysis and Predialysis. Open Urol Nephrol J, 2024; 17: e1874303X304324. ttp://dx.doi.org/10.2174/011874303X304324240529133609
  • Updated results from the RUBY-3 study of Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. Kidney International Reports, Vol 9 (4), S 505 (April 2024)
  • Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. Kidney International Reports, Vol 9 (4), S-141 (April 2024)
  • Updated results from the RUBY-3 study of Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. NDT (Neph Dial Transp Vol 39, Issue Supplement 1, 0431- (May 2024)
  • Prophylactic antibiotics before insertion of tunneled hemodialysis catheters: A Nationwide Cohort Study. Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN.
  • Younger adults were disproportionately affected by hemodialysis catheter infections in Australia: A Prospective Nationwide Cohort Study. Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN
  • Replacement Strategies for Tunnelled Hemodialysis Catheters with Complications: A Nationwide Cohort Study Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN
  • Casey Light, Karen Heslop, HEMANT KULKARNI: Hepatitis B vaccination in patients with stage 4/5 chronic kidney disease – a scoping review. Renal Society of Australasia Journal 2023; 19(1):68-76.
  • Smyth, B., Kotwal, S., Gallagher, M., Gray, N. A., & Polkinghorne, K. (2018). Dialysis catheter management practices in Australia and New Zealand. Nephrology (Carlton). 2018 Sep 28. . Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30267459. doi:10.1111/nep.13507
  • Light C; Kulkarni H (Mar 2018). Booster hepatitis B vaccination in haemodialysis patients: Five-year prospective observational study Renal Society of Australasia Journal
  • Holman, R, Olynyk, JK, Kulkarni, H and Ferrari, P (2017), Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology, Feb 2017, doi: 10.1111/nep.12735.
  • SD Roger, CA Gaillard, AH Bock, F Carrera…H Kulkarni (As Investigator Group)… et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2016 doi: 10.1093/ndt/gfw26
  • Hoy, W. E., H. G. Healy, D. Waugh, M. D. Jose, H. Kulkarni, I. Katz, C. Nelson, K. Panaretto, and R. Walker. “Towards a national surveillance network for chronic kidney disease (CKD).” In Nephrology, vol. 19, pp. 58-88. 2014.
  • Casey Light, Hemant Kulkarni. TOLERABILITY AND SAFETY OF RAPID INTRAVENOUS PUSH BOLUS ADMINISTRATION OF IRON POLYMALTOSE 200MG OVER 15 MINUTES ON HAEMODIALYSIS: A PILOT STUDY. ANZSN Presentation . Nehrology Aug 2024
  • AL Graves, M Texler, L Manning, H Kulkarni. Successful treatment of renal allograft and bladder malakoplakia with minimisation of immunosuppression and prolonged antibiotic therapy. Nephrology, Vol 19, Suppl 1, 18-21, April 2014.
  • H Kulkarni, N Lenzo, A McLean‐Tooke. Causality of rhabdomyolysis and combined tetanus, diphtheria and acellular pertussis (Tdap) vaccine administration. The Journal of Clinical Pharmacology 53 (10), 1099-1102, 2013
  • Jo Ryan, Hemant Kulkarni, P Ferrari. SERUM GENTAMICIN MONITORING IS NOT WARRANTED WITH USE OF GENTAMICIN CITRATE LOCKS FOR HAEMODIALYSIS CENTRAL VENOUS CATHETER (CVC). ANZSN, Sept 2013
  • DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al… The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: the balANZ Trial  Peritoneal Dialysis International 32 (5), 497-506 ; 2012DW
  • Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al… Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes J Am Soc Nephrol 23, 1097-1107 , 2012
  • DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al… The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrology Dialysis Transplantation. 2012
  • Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St. Pierre T, and Olynyk J. Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease Clin J Am Soc Nephrol Jan 2011 (Published online on September 28, 2010 as doi:10.2215/CJN.04190510)
  • Clark BM, Boan P, Kulkarni H. A Case of Legionella longbeachae Pneumonia Complicated by Rhabdomyolysis and Acute Renal Failure Requiring Hemodialysis. Infectious Diseases in Clinical Practice. 18(6):413-416, November 2010.
  • JK Olynyk, P Ferrari, H Kulkarni, TC Tan, D Trinder. Non-invasive characterisation of significant hepatic iron overload in hyperferritinemic subjects HEPATOLOGY, Vol 48, Issue 4, 1170A, 2008
  • Singer R, Rhodes H, Chin G, Kulkarni H, Ferrari P. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton), 2008: Volume 13 Issue 1 Page 17-22.Howman H, Kulkarni H. Antibody-mediated acquired Pure Red Cell Aplasia after treatment with darbepoetin – Nephrology Dialysis Transplantation 2007 22(5):1462-1464.
  • Thomas MA, Luxton G, Moody HR, Woodroffe AJ, Kulkarni H, Lim W, Christiansen FT, Opelz G. Subjective and quantitative assessment of patient fitness for cadaveric kidney transplantation: the “equity penalty”. Transplantation. 2003 Apr 15;75(7):1026-9.
  • H Kulkarni, K Jureidini, P Trnka, P Henning, R Vigneswaran, S Harris
    Cystatin C is a promising marker of renal function in newborns during first 3 months. Nephrology Dialysis Transplantation 18 (18 (suppl 4): 808-813.), 808-813 2003
  • Playford D, Kulkarni H, Thomas M, Vivian J, Low A, Mander J, Perlman D, Finch P. Intra-ureteric capsaicin in loin pain haematuria syndrome: efficacy and complications. British Journal of Urology Int. 2002 Oct;90(6):518-21.
  • Kulkarni H, Goldwater PN, Martin A, Bettelheim KA. Escherichia coli ‘O’ group serological responses and clinical correlations in epidemic HUS patients. Comp Immunol Microbiol Infect Dis. 2002 Jul;25(4):249-68.
  • H Kulkarni, S Bichu, U Oza, A Kirpalani. Sulphonamide crystalluria induced acute renal failure in a renal allograft. —A case report,
    Indian Journal of Nephrology, Vol 7, No 1, 20-21, Jan-Mar 1997.
  • Patnekar PN, Kulkarni HA, Khopkar SR, Kulkarni VS, Nerurkar RS. Nevus flammeus in tuberous sclerosis Indian Pediatr. 1995 Sep;32(9):1038-9.
  • H KULKARNI: Antiphospholipid Syndrome in a single kidney- A case report: Indian Journal of Renal Sciences, 1999.
  • H KULKARNI: Can Cystatin C replace creatinine as a marker of renal function? Review article in Indian Journal of Renal Sciences, 1999.

CURRENT TRIALS:

Hepatitis B Vaccination in Advanced CKD – Stage 4 v/s Stage 5

Safety and tolerability of Metformin in Advanced CKD – GEKO Approved Study in progress

Safety and Tolerability of GLP1 analogues in Advanced CKD – GEKO Approved Study in Progress

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD (MRI and Echo Substudy) https://classic.clinicaltrials.gov/ct2/show/NCT05374291

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD) – https://classic.clinicaltrials.gov/ct2/show/NCT04724837

RUBY – 3 Trial – IgA (Closed for recruitment); SLE; Memb GN (Closed for recruitment), ANCA associated vasculitis:
Impressive results with auto antibody reduction
https://www.alpineimmunesciences.com/wp-content/uploads/2024/04/WCN-2024-RUBY-3-LB-poster_FINAL.pdf

ALXN1210-IgAN-320: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN): IgA Nephropathy with proteinuria and biopsy

PHOSPHATE Study – Recruitment closed and followup extended for another 2 years (2026)

BEAT – CALCI TRIAL: Calciphylaxis on dialysis (Started – August 2024)